Abstract:Liver metastases (i.e. secondary hepatic malignancies) are significantly more common than primary liver cancer. Long‐term survival after radical surgical treatment is approximately 50%. For people in whom resection for cure is not feasible, other treatments must be considered. One treatment option is microwave coagulation utilising electromagnetic waves. It involves placing an electrode into a lesion under ultrasound or computed tomography guidance. To evaluate the beneficial and harmful effects of microwave coagulation versus no intervention, other ablation methods, or systemic treatments in people with liver metastases regardless of the location of the primary tumour. We used standard, extensive Cochrane search methods. The latest date of search was 14 April 2023. Randomised clinical trials assessing beneficial or harmful effects of microwave coagulation and its comparators in people with liver metastases, irrespective of the location of the primary tumour. We included trials no matter the outcomes reported. We followed standard Cochrane methodological procedures. Our primary outcomes were: all‐cause mortality at the last follow‐up and time to mortality; health‐related quality of life (HRQoL); and any adverse events or complications. Our secondary outcomes were: cancer mortality; disease‐free survival; failure to clear liver metastases; recurrence of liver metastases; time to progression of liver metastases; and tumour response measures. We used risk ratios (RR) and hazard ratios (HR) with 95% confidence intervals (CI) to present the results. Two review authors independently extracted data and assessed the risk of bias using the Cochrane RoB 1 tool. We used GRADE methodology to assess the certainty of the evidence. Three randomised clinical trials fulfilled the inclusion criteria. The control interventions differed in the three trials; therefore, meta‐analyses were not possible. The trials were at high risk of bias. The certainty of evidence of the assessed outcomes in the three comparisons was very low. Data on our prespecified outcomes were either missing or not reported. Microwave coagulation plus conventional transarterial chemoembolisation (TACE) versus conventional TACE alone One trial, conducted in China, randomised 50 participants (mean age 60 years, 76% males) with liver metastases from various primary sites. Authors reported that the follow‐up period was at least one month. The trial reported adverse events or complications in the experimental group only and for tumour response measures. There were no dropouts in the trial. The trial did not report on any other outcomes. Microwave ablation versus conventional surgery One trial, conducted in Japan, randomised 40 participants (mean age 61 years, 53% males) with multiple liver metastases of colorectal cancer. Ten participants were excluded after randomisation (six from the experimental and four from the control group); thus, the trial analyses included 30 participants. Follow‐up was three years. The reported number of deaths from all causes was 9/14 included participants in the microwave group versus 12/16 included participants in the conventional surgery group. The mean overall survival was 27 months in the microwave ablation and 25 months in the conventional surgery group. The three‐year overall survival was 14% with microwave ablation and 23% with conventional surgery, resulting in an HR of 0.91 (95% CI 0.39 to 2.15). The reported frequency of adverse events or complications was comparable between the two groups, except for the required blood transfusion, which was more common in the conventional surgery group. There was no intervention‐related mortality. Disease‐free survival was 11.3 months in the microwave ablationgroup and 13.3 months in the conventional surgery group. The trial did not report on HRQoL. Microwave ablation versus radiofrequency ablation One trial, conducted in Germany, randomised 50 participants (mean age 62.8 years, 46% males) who were followed for 24 months. Two‐year mortality showed an RR of 0.62 (95% CI 0.26 to 1.47). The trial reported that, by two years, 76.9% of participants in the microwave ablationgroup and 62.5% of participants in the radiofrequency ablation group survived (HR 0.63, 95% CI 0.23 to 1.73). The trial reported no deaths or major complications during the procedures in either group. There were two minor complications only in the radiofrequency ablation group (RR 0.19, 95% CI 0.01 to 3.67). The trial reported technical efficacy in 100% of procedures in both groups. Distant recurrence was reported for 10 participants in the microwave ablation group and nine participants in the radiofrequency ablation group (RR 1.03, 95% CI 0.50 to 2.08). No participant in the microwave ablation group demonstrated local progression at 12 months, while that occurred in two participants in the radiofrequency ablation group (RR 0.19, 95% CI 0.01 t -Abstract Truncated-

Microwave Surgery in the Treatment of Hepatocellular Carcinoma

Microwave ablation in combination with TACE for the treatment of primary hepatic carcinoma

915-Mhz Microwave-Assisted Laparoscopic Hepatectomy: a New Technique for Liver Resection

Clinical Assessment of Sonographically Guided Microwave Coagulation Therapy in Patients with Liver Carcinoma

Use of microwave tissue coagulator in hepatocellular carcinoma resection: compared with Lin's hepatic clamp.

Investigation on the clinical application of microwave ablation in the treatment of liver cancer

Laparoscopic Microwave Ablation of Hepatocellular Carcinoma at Liver Surface: Technique Effectiveness and Long-Term Outcomes.

Analysis of the Clinical Efficacy of Liver Resection Combined with Adjuvant Microwave Coagulation for Patients with Hepatocellular Carcinoma

[Clinical Application of Microwave Ablation in Potentially Resectable Colorectal Cancer With Simultaneously Multiple Liver Metastases]

Surgical microwave ablation for the treatment of hepatocellular carcinoma in 791 operations

Microwave Ablation Combined with Hepatectomy for Treatment of Neuroendocrine Tumor Liver Metastases.

Ultrasound guided percutaneous microwave coagulation therapy for liver carcinoma:32 cases clinical analysis

Clinical research on the cold-cycle microwave ablation in combination with TACE in the treatment of primary hepatocarcinoma

Efficacy of laparoscopic microwave ablation in treatment of malignant liver tumors

Microwave coagulation for liver metastases

Laparoscopic Hepatectomy Versus Microwave Ablation for Multifocal 3-5Cm Hepatocellular Carcinoma: a Multi-center, Real-world Study

Making liver transection even safer: a novel use of microwave technology

Percutaneous and open-approach microwave ablation in the treatment of a patient with colon cancer and multiple hepatic metastases

Microwave Ablation Combined with Transarterial Chemoembolization Containing Doxorubicin Hydrochloride Liposome for Treating Primary and Metastatic Liver Cancers.

Combined laparoscopic hepatectomy and microwave ablation for multifocal liver neoplasms

A comparison between microwave ablation and surgical resection for small hepatocellular carcinoma